查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1854005

细胞和基因治疗临床试验市场（按治疗类型、载体类型、细胞类型、适应症和试验阶段划分）—2025-2032年全球预测

Cell & Gene Therapy Clinical Trials Market by Therapy Type, Vector Type, Cell Type, Indication, Trial Phase - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2032 年，细胞和基因治疗临床试验市场将成长至 323.8 亿美元，复合年增长率为 15.14%。

关键市场统计数据
基准年2024年 104.8亿美元
预计年份：2025年 120.8亿美元
预测年份 2032 323.8亿美元
复合年增长率 (%) 15.14%

全面介绍影响细胞和基因治疗临床试验及策略计画选择的临床、生产和监管因素。

细胞和基因治疗临床试验生态系统正处于关键的十字路口，其发展受到快速的科学成熟、不断变化的监管预期以及不断变化的商业性需求的共同影响。过去十年，细胞工程、病毒和非病毒递送平台以及製程分析的创新催生了更广泛、更多样化的研发管线。因此，曾经专注于自体疗法的计画如今正转向异体疗法、复杂的载体设计以及融合分散式和集中式能力的混合生产模式。

在这种环境下，相关人员需要在科学抱负与切实可行的营运计画之间取得平衡。申办者必须将临床开发设计与供应链韧性、载体采购安全性和生产扩充性结合。投资者和合作伙伴机构正日益仔细地审查开发路径，以明确转化风险、监管合规性和商业化准备。因此，能够将强大的转化科学与可验证的生产计划和监管关係相结合的临床试验赞助者，将能够高效地推进治疗方法进入临床并最终获得应用。

鑑于生物学、物流和政策之间错综复杂的相互作用，将治疗方式、载体策略、细胞类型选择、适应症优先排序和临床试验阶段顺序联繫起来的整体观点至关重要。本报告将这些维度整合为一个连贯的叙述，为贯穿整个研发生命週期的专案策略决策和营运执行提供支援。

研发模式、生产自动化和监管科学的突破如何重新定义临床研发路径和商业化准备

由于递送系统、生产自动化和监管科学的进步，细胞和基因疗法的临床开发模式正在发生显着变化。递送技术正从传统的病毒载体扩展到更先进的非病毒载体，例如电穿孔和脂质奈米颗粒系统，从而实现更安全、更灵活的基因转移策略，并开拓新的适应症。同时，载体工程和衣壳设计的创新正在改善组织靶向性和免疫抗原性原性，促使临床项目重新思考以往关于治疗方法和患者选择的决策。

生产现代化同样至关重要。采用封闭式系统、一次性技术和强化纯化策略，提高了製程稳健性和可重复性的标准。这些改进降低了批次差异，缩短了週期时间，并促进了自体和异体模型的规模化应用。监管机构也积极回应，完善了效力检测法、可比性框架和长期追踪要求的指导，敦促临床团队将监管考虑融入早期研究设计中。

最后，商业和临床策略正朝着适应症特异性优化方向发展。肿瘤研发管线正日益转向针对骨髓恶性肿瘤和固态肿瘤的差异化治疗方案，而神经病学和罕见疾病计画则致力于实现持续的中枢神经系统给药和单剂量治疗。总而言之，这些转变需要整合研发计划，将科学创新与可生产性、监管途径和长期患者用药策略相结合。

评估关税引发的供应链压力和成本上涨对临床试验连续性和生产方案的营运和策略影响

近期贸易政策的发展以及2025年关税的实施，为细胞和基因治疗临床计画的规划计算引入了新的变数。关税对关键投入品、专用设备和跨境服务的累积影响，凸显了供应链透明度和供应商多元化的重要性。实验室和製造商在采购病毒载体、一次性耗材和高等级试剂时，如今更加密切地评估总土地成本和前置作业时间波动，这影响着他们选择国内采购还是国际采购，以及是否需要储备更多符合GMP标准的物料安全库存。

为此，各组织正加快推进关键供应链本地化，并对载体生产、关键原材料和生物加工设备的二级供应商合格。这一趋势与对本地生产能力的策略性投资以及与合约研发受託製造厂商）的合作相辅相成，从而降低关税相关中断带来的风险。同时，关税带来的成本压力也奖励企业致力于製程优化和产量比率提升，以降低每剂疫苗的材料消费量和对进口成分的依赖。

从营运角度来看，申办方正在调整临床试验预算，以应对日益复杂的物流、潜在的海关延误以及不断上涨的低温运输运输成本。这些调整会影响试验中心的选择、受试者招募策略以及多区域试验的时间表。总而言之，关税政策的变化凸显了製定动态临床实验链策略、与製造商和物流供应商密切合作以及进行情境规划的必要性，以确保试验的连续性和临床进展。

利用综合细分框架，将治疗方式、载体技术、细胞来源、适应症和临床试验阶段连结起来，从而优先制定临床和生产策略。

细緻的细分方法揭示了治疗方式、载体技术、细胞来源、适应症和临床阶段如何相互交织，从而影响专案的风险和机会。根据治疗类型，该领域涵盖细胞疗法、基因疗法和组织工程产品。细胞疗法计画进一步细分为CAR-T细胞疗法、树突细胞疗法、NK细胞疗法和干细胞疗法。基因疗法策略分为非病毒载体和病毒载体，其中非病毒载体包括电穿孔、脂质奈米颗粒和裸核酸等方法，病毒载体包括腺结合病毒、腺病毒和逆转录病毒系统等。这种分层分类法阐明了科学选择如何影响生产的复杂性和监管参与。

对载体类型进行分类，包括非病毒载体和病毒载体，是风险评估的基础。虽然病毒载体具有高效基因转移和持久表达的优势，但载体递送、免疫反应和衣壳选择等方面仍需考虑。对细胞类型进行分类则突显了操作上的权衡取舍。树突细胞和NK细胞的疗效检测方法和给药方案各不相同；干细胞需要谱系特异性处理，并分为造血干细胞和间质干细胞亚型；T细胞策略则分为CAR-T细胞和TCR细胞，二者在生产和临床监测方面存在差异。

基于适应症的细分阐明了治疗意图如何定义临床设计。针对阿兹海默症和帕金森氏症的神经病学计画面临着血脑障壁递送和长期安全性监测的需求。肿瘤学研究必须区分血液系统癌症（如白血病和淋巴瘤）与固体癌（如乳癌和黑色素瘤），尤其是在肿瘤微环境调控方面。以遗传和代谢性疾病（如囊肿纤维化和血友病）为中心的罕见疾病研究优先考虑持续的性能改进和新生儿筛检的整合。从I期到III期的临床试验细分凸显了日益提高的监管期望、对商业规模生产计划日益增长的需求，以及证据重点从安全性和概念验证转向更广泛的疗效、持久性和真实世界应用性。这些细分视角为优先考虑研发投资和管理资源的分配提供了一个全面的框架。

区域法律规范、生产能力和临床基础设施如何驱动具有全球影响力的差异化发展策略

区域因素对研究设计、製造地和监管规划等策略决策有显着影响。在美洲，成熟的投资者基础和完善的临床基础设施推动了早期和晚期项目的开展，集中了血液肿瘤领域的专业知识和先进的生产製造创新，支持自体和异体移植。该地区的监管工作日益侧重于长期安全性监测和核准后承诺，这些因素正在影响证据产生计画和后续方案的发展。

在欧洲、中东和非洲，监管环境既存在协调统一的机会，也存在各国差异。欧洲监管机构和卫生技术评估机构需要可靠的疗效和安全性比较数据，这些数据会影响终点选择和伴随诊断策略。同时，这些地区的新兴市场拥有极具吸引力的罕见疾病和神经病学临床试验患者群体，但需要在伦理、基础设施准备和供应链物流方面进行周密规划。

亚太地区的特点是产能快速扩张、公共对生物製造的定向投资，以及临床试验中心数量不断增加，这些中心在基因和细胞治疗研究方面经验日益丰富。各地法律规范正在不断发展以适应先进疗法，各国政府鼓励发展国内生产能力以加速区域市场准入，但这可能也会在智慧财产权和人才方面造成动态。在整个亚太地区，申办方都在努力平衡临床试验速度、监管合规性和本地营运可行性，以成功实施其全球发展策略。

高绩效组织如何透过平台专业化、策略製造伙伴关係以及整合转换和商业规划脱颖而出

细胞和基因治疗领域的主要企业和机构在技术平台、生产模式和治疗重点领域均展现出策略多元化。一些公司专注于载体设计、衣壳工程和非病毒递送系统等平台技术，从而能够跨多个专案共用研发和製程开发投资。另一些机构则优先考虑细胞类型专业化，致力于在干细胞分化、NK细胞生物学和T细胞工程方面积累深厚的专业知识，以在特定适应症中获得临床和转化优势。

与合约开发和受託製造公司的合作关係日益趋向于长期策略联盟，其中包括联合製程优化、技术转移和共用生产力计画。企业也在投资内部生产，因为对关键品质属性和时间节点的控制是其提案主张的核心，同时选择性地进行外包，以保持灵活性和成本控制。智慧财产权策略优先考虑载体平台和给药方式的自由，许多公司正在利用生物标记特征和数位试验终点等数据主导资产来补充其核心智慧财产权，以加强与监管机构和支付方的互动。

最后，该领域的领导力通常与将转化科学与商业性远见结合的能力密切相关。在研发早期就协调好临床方案、生产规模化和市场推广计画的团队，能够减少后续环节的摩擦，并加速病患获得治疗的速度。

优先营运建议，旨在加强供应链、标准化平台，并协调监管和商业计划，以实现专案的持续成功。

产业领导者应采取一系列切实有效、影响深远的行动，以克服科学上的复杂性和营运上的限制。首先，在专案规划中建构供应链韧性，具体措施包括：确定多个载体和关键材料供应商；投资建设符合GMP标准的耗材策略库存缓衝；以及评估区域生产伙伴关係关係，以降低贸易中断的风险。其次，加快平台协调：在所有产品组合中标准化核心单元操作、检测方法和效力指标，以缩短研发週期并简化可比性评估。

第三，儘早与监管机构沟通，为临床和生产决策提供资讯。及时与监管机构展开对话，明确长期追踪预期、可比较标准以及新型递送系统的要求。即使载体和细胞产量只有小幅提升，也能显着降低下游物流负担和成本敏感度。第五，制定商业策略，将健康经济学终点和真实世界数据收集纳入关键试验设计和核准后计划，从而满足支付方的证据需求。

最后，透过投资组成能够连结生物学、程式工程、法规事务和市场进入领域的团队，发展跨职能能力。这种组织上的协调一致有助于在不确定性下更快地做出决策，更顺畅地进行技术转移，并在与合作伙伴和支付方的谈判中占据更有利的地位。实施这些措施将有助于确保近期临床试验的顺利进行，并最终实现长期的商业成功。

结合专家访谈、监管审查和情境分析的稳健混合方法，能够提供针对具体项目且具有实际操作意义的见解。

本分析的调查方法采用定性方法，整合临床开发趋势、监管指南审查和跨行业商业实践，以得出可操作的见解。主要资料来源包括对临床开发负责人、生产和供应链高管以及监管事务专家的结构化访谈，并辅以同行评审文献、监管文件和产品特定技术披露。分析重点在于透过资讯来源交叉验证，以检验观察到的变化，包括给药技术、流程改善和区域产能扩张。

分析师应用了一个细分框架，该框架整合了治疗方式、载体类型、细胞生物学、适应症和临床试验阶段，以确保提供特定情况的建议。情境分析用于评估贸易政策变化、供应链衝击和製造创新对临床实验连续性和专案经济效益的影响。在条件允许的情况下，方法论透明化，记录了关于供应链依赖性、监管时间表和技术成熟度水准的假设。

调查方法的局限性包括：快速变化的临床数据和独特的生产流程可能会改变专案进度轨迹，而地方监管决策也可能根据新出现的证据进行调整。为了弥补这些局限性，该方法强调定期更新建议，并提供针对特定项目和伙伴关係情况的深入分析选项。

一份简明扼要的策略要务概要，旨在将科学创新与营运韧性相结合，以推进临床项目并改善患者就医途径。

总之，细胞和基因治疗临床试验领域正处于曲折点，科学机会与日益复杂的运作环境交汇融合。递送技术、载体工程和生产自动化方面的进步正在为更广泛的治疗效果铺平道路，但这些进步也伴随着供应链脆弱性、监管审查以及对规模化生产解决方案的需求。积极整合治疗方式选择、载体策略、细胞来源考量、适应症特异性设计以及符合各阶段研究证据产生的申办方，将能更有效地降低研发风险。

区域动态和近期贸易政策发展进一步凸显了建构具有韧性的供应链、多元化的製造地以及精心安排的监管合作的重要性。成功的专案需要组建跨职能团队，将转化科学与製程开发和商业性远见相结合，并执行复杂且相互关联的目标。最终，那些尽可能优先考虑标准化、在必要时保持灵活性并与监管机构和生产合作伙伴保持密切对话的组织，将更有能力将临床创新转化为永续的患者获益。

目录

第一章：序言

第二章调查方法

第三章执行摘要

第四章 市场概览

第五章 市场洞察

  • 利用现成解决方案扩展针对固态肿瘤的同种异体CAR-T疗法
  • 将碱基编辑等基因编辑工具整合到血友病检测中，以提高其安全性。
  • 采用新一代病毒载体提升T细胞疗法的传递效率
  • 开发用于体内基因治疗的非病毒递送平台以降低免疫抗原性
  • 实施分散式製造模式，以全球扩大细胞疗法生产规模

第六章：美国关税的累积影响，2025年

第七章：人工智慧的累积影响，2025年

8. 按治疗类型分類的细胞和基因治疗临床试验市场

  • 细胞疗法
    • CAR-T细胞
    • 树突细胞疗法
    • NK细胞疗法
    • 干细胞疗法
  • 基因治疗
    • 非病毒载体
      • 电穿孔
      • 脂质奈米颗粒
      • 裸露的DNA/RNA
    • 病毒载体
      • 腺结合病毒
      • 腺病毒
      • 逆转录病毒
  • 组织工程产品

9. 按载体类型分類的细胞和基因治疗临床试验市场

  • 非病毒载体
    • 电穿孔
    • 脂质奈米颗粒
    • 裸露的DNA/RNA
  • 病毒载体
    • 腺结合病毒
    • 腺病毒
    • 逆转录病毒

第十章：按细胞类型分類的细胞和基因治疗临床试验市场

  • 树突状细胞
  • NK细胞
  • 干细胞
    • 造血干细胞
    • 间质干细胞
  • T细胞
    • CAR T
    • TCR

第十一章：按适应症分類的细胞和基因治疗临床试验市场

  • 神经病学
    • 阿兹海默症
    • 帕金森氏症
  • 肿瘤学
    • 血癌
      • 白血病
      • 淋巴瘤
    • 固态肿瘤
      • 乳癌
      • 黑色素瘤
  • 罕见疾病
    • 遗传性疾病
      • 囊肿纤维化
      • 血友病
    • 代谢紊乱

第十二章：按试验阶段分類的细胞和基因治疗临床试验市场

  • 第一阶段
  • 第二阶段
  • 第三阶段

第十三章：按地区分類的细胞和基因治疗临床试验市场

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十四章：细胞与基因治疗临床试验市场（按组别划分）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十五章：各国细胞与基因治疗临床试验市场

  • 美国
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十六章 竞争格局

  • 2024年市占率分析
  • FPNV定位矩阵，2024
  • 竞争分析
    • Novartis AG
    • Gilead Sciences, Inc.
    • Spark Therapeutics, Inc.
    • bluebird bio, Inc.
    • Sangamo Therapeutics, Inc.
    • CRISPR Therapeutics AG
    • Editas Medicine, Inc.
    • Fate Therapeutics, Inc.
    • Orchard Therapeutics Ltd
    • uniQure NV
Product Code: MRR-0D217D5AEB5A

The Cell & Gene Therapy Clinical Trials Market is projected to grow by USD 32.38 billion at a CAGR of 15.14% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 10.48 billion
Estimated Year [2025] USD 12.08 billion
Forecast Year [2032] USD 32.38 billion
CAGR (%) 15.14%

A panoramic introduction to the clinical, manufacturing, and regulatory forces reshaping cell and gene therapy trials and strategic program choices

The cell and gene therapy clinical trials ecosystem stands at a pivotal juncture, shaped by rapid scientific maturation, evolving regulatory expectations, and shifting commercial imperatives. Over the past decade, innovations in cell engineering, viral and non-viral delivery platforms, and process analytics have translated into a broader and more diverse pipeline. As a result, programs that once focused narrowly on autologous approaches are now pursuing allogeneic strategies, refined vector design, and hybrid manufacturing models that blend decentralized and centralized capabilities.

This environment demands that stakeholders balance scientific ambition with pragmatic operational planning. Sponsors must integrate clinical development design with supply chain resilience, vector sourcing security, and manufacturing scalability. Investors and partner organizations are increasingly scrutinizing development pathways for clarity on translational risk, regulatory alignment, and commercialization readiness. Consequently, trial sponsors that align robust translational science with demonstrable manufacturing plans and regulatory engagement are better positioned to progress therapies efficiently through the clinic and toward adoption.

Given the complex interplay of biology, logistics, and policy, a holistic view that connects therapeutic modality, vector strategy, cell type selection, indication prioritization, and trial phase sequencing is essential. This report synthesizes those dimensions into a coherent narrative that supports strategic decision-making and operational execution for programs across the development lifecycle.

How breakthroughs in delivery modalities, manufacturing automation, and regulatory science are redefining clinical development pathways and commercialization readiness

The landscape of clinical development for cell and gene therapies is undergoing transformative shifts driven by advances in delivery systems, manufacturing automation, and regulatory science. Delivery technologies have expanded beyond traditional viral constructs into sophisticated non-viral approaches such as electroporation and lipid nanoparticle systems, which are enabling safer, more flexible gene transfer strategies and opening new indications. Concurrently, vector engineering and capsid design innovations are improving tissue targeting and immunogenicity profiles, encouraging clinical programs to revisit earlier decisions about modality and patient selection.

Manufacturing modernization is equally consequential. Adoption of closed systems, single-use technologies, and intensified purification strategies has raised the bar for process robustness and reproducibility. These improvements reduce batch variability and shorten cycle times, promoting the feasibility of both autologous and allogeneic models at scale. Regulatory authorities are responding by refining guidance on potency assays, comparability frameworks, and long-term follow-up requirements, which requires clinical teams to embed regulatory thinking into early-stage trial design.

Finally, commercial and clinical strategy is evolving toward indication-specific optimization. Oncology pipelines increasingly differentiate approaches between hematologic malignancies and solid tumors, while neurology and rare disease programs seek durable central nervous system delivery and single-administration treatments. Taken together, these shifts demand integrated development plans that align scientific innovation with manufacturability, regulatory pathways, and long-term patient access strategies.

Assessing the operational and strategic ripple effects of tariff-induced supply chain pressures and cost inflation on clinical trial continuity and manufacturing choices

Recent trade policy developments and tariff actions in 2025 have introduced new variables into the planning calculus for cell and gene therapy clinical programs. The cumulative effects of tariffs on critical inputs, specialized equipment, and cross-border services have elevated the importance of supply chain visibility and supplier diversification. Labs and manufacturers sourcing viral vectors, single-use consumables, and high-grade reagents are now evaluating total landed costs and lead-time volatility more rigorously, which influences decisions on domestic versus international procurement and on holding higher safety stocks for GMP materials.

In response, organizations are accelerating efforts to localize key supply chains and to qualify secondary suppliers for vector production, critical raw materials, and bioprocess equipment. This trend intersects with strategic investments in regional manufacturing capacity and contract development and manufacturing organization partnerships that reduce exposure to tariff-related disruptions. At the same time, tariff-driven cost pressure is incentivizing process optimization and yield improvement initiatives that lower per-dose material consumption and reliance on imported components.

From an operational perspective, sponsors are recalibrating clinical trial budgets to reflect increased logistics complexity, potential customs delays, and heightened costs for specialized cold-chain transportation. These adjustments influence trial site selection, enrollment strategies, and timelines for multi-regional studies. In sum, the tariff landscape underscores the need for dynamic supply chain strategies, closer collaboration with manufacturers and logistics providers, and scenario planning to maintain trial continuity and clinical momentum.

A comprehensive segmentation framework connecting modality, vector technology, cell source, indication focus, and trial phase to prioritize clinical and manufacturing strategies

A nuanced segmentation approach reveals how modality, vector technology, cellular source, indication, and clinical phase intersect to shape program risks and opportunities. Based on therapy type, the field spans cell therapy, gene therapy, and tissue-engineered products; cell therapy programs further differentiate into CAR T cell, dendritic cell therapy, NK cell therapy, and stem cell therapy, while gene therapy strategies split between non-viral and viral vectors, with non-viral options such as electroporation, lipid nanoparticle, and naked nucleic acid approaches and viral options including adeno-associated virus, adenoviral, and retroviral systems. This layered taxonomy clarifies how scientific choices influence manufacturing complexity and regulatory engagement.

Drawing from vector type segmentation, the distinction between non-viral and viral approaches is foundational to risk profiling. Non-viral methods offer advantages in manufacturability and immunogenicity control, with electroporation and lipid nanoparticle platforms enabling transient expression or precise delivery, whereas viral vectors retain strengths in efficient gene transfer and durable expression but introduce considerations around vector supply, immunological response, and capsid selection. Cell type segmentation highlights operational trade-offs; dendritic cells and NK cells present distinct potency assays and dosing paradigms, stem cells require lineage-specific handling and may be divided into hematopoietic and mesenchymal subtypes, and T cell strategies bifurcate into CAR T and TCR approaches with divergent manufacturing and clinical monitoring needs.

Indication-based segmentation underscores how therapeutic objectives define clinical design. Neurology programs targeting Alzheimer's and Parkinson's disease face blood-brain barrier delivery and long-term safety monitoring imperatives, oncology efforts must differentiate hematologic cancers such as leukemia and lymphoma from solid tumors like breast cancer and melanoma with respect to tumor microenvironment modulation, and rare disease initiatives centered on genetic and metabolic disorders such as cystic fibrosis and hemophilia prioritize durable systemic correction and newborn screening linkages. Trial phase segmentation-from Phase I through Phase III-illuminates the escalation of regulatory expectations, the increasing need for commercial-scale manufacturing plans, and the shift in evidence focus from safety and proof-of-concept toward broader efficacy, durability, and real-world applicability. Together, these segmentation lenses provide a comprehensive framework for prioritizing development investments and allocating operational resources.

How regional regulatory frameworks, manufacturing capacities, and clinical infrastructure drive differentiated development strategies across global footprints

Regional dynamics materially influence strategic decisions in trial design, manufacturing footprint, and regulatory planning. In the Americas, a mature investor base and extensive clinical infrastructure have propelled early and late-stage programs, with concentrated expertise in hematologic oncology and advanced manufacturing innovation that supports both autologous and allogeneic approaches. Regulatory engagement in this region increasingly emphasizes long-term safety monitoring and post-approval commitments, thereby shaping evidence generation plans and follow-up protocols.

Across Europe, the Middle East, and Africa, the regulatory landscape exhibits both harmonization opportunities and national nuances. European regulatory authorities and health technology assessment bodies require robust comparative effectiveness and safety data, which affects endpoint selection and companion diagnostics strategies. Meanwhile, emerging markets within these regions present attractive patient populations for rare diseases and neurology trials, but they necessitate careful planning around ethics, infrastructure readiness, and supply chain logistics.

The Asia-Pacific region is characterized by rapid capacity expansion, targeted public investment in biomanufacturing, and growing clinical trial centers with increasing experience in gene and cell therapy studies. Local regulatory frameworks are evolving to accommodate advanced therapeutics, and governments are incentivizing domestic manufacturing capabilities, which can accelerate regional access but also create competitive dynamics for intellectual property and talent. Across all regions, sponsors are balancing speed to clinic with regulatory alignment and local operational feasibility to ensure successful global development strategies.

What differentiates high-performing organizations through platform specialization, strategic manufacturing partnerships, and integrated translational-commercial planning

Leading companies and institutions in the cell and gene therapy space demonstrate strategic diversity across technology platforms, manufacturing models, and therapeutic focus areas. Some organizations concentrate on platform technologies that address vector design, capsid engineering, or non-viral delivery systems, enabling multiple programs to leverage shared R&D and process development investments. Others prioritize cell-type specialization, building deep expertise in stem cell differentiation, NK cell biology, or T cell engineering to create clinical and translational advantages in specific indications.

Partnership models have evolved to reflect operational realities; alliances with contract development and manufacturing organizations are increasingly structured as long-term strategic collaborations that include joint process optimization, technology transfer, and shared capacity planning. Companies are also investing in in-house manufacturing where control of critical quality attributes and timelines is central to their value proposition, while selectively outsourcing to maintain flexibility and cost discipline. Intellectual property strategies prioritize freedom to operate around vector platforms and delivery modalities, and many organizations are complementing core IP with data-driven assets such as biomarker signatures and digital trial endpoints to strengthen regulatory and payer dialogues.

Finally, leadership in the field often correlates with the ability to integrate translational science with commercial foresight-teams that align clinical protocols, manufacturing scale-up, and market-access planning early in development reduce downstream friction and accelerate patient access.

Priority operational recommendations to fortify supply chains, standardize platforms, and align regulatory and commercial plans for durable program success

Industry leaders should pursue a set of pragmatic, high-impact actions to navigate scientific complexity and operational constraints. First, embed supply chain resilience into program planning by qualifying multiple vector and critical-material suppliers, investing in strategic inventory buffers for GMP consumables, and evaluating regional manufacturing partnerships that reduce exposure to trade disruptions. Second, accelerate platform harmonization: standardize core unit operations, assay panels, and potency metrics across portfolios to reduce development timelines and simplify comparability assessments.

Third, align early regulatory engagement with clinical and manufacturing decisions. Initiate timely dialogues with regulators to clarify long-term follow-up expectations, comparability criteria, and requirements for novel delivery systems. Fourth, prioritize scalable process improvements that reduce material consumption and increase yield; even modest gains in vector or cell yield can materially reduce downstream logistical burden and cost sensitivity. Fifth, structure commercial strategies that anticipate payer evidence needs by integrating health economics endpoints and real-world data collection into pivotal study designs and post-approval plans.

Lastly, cultivate cross-functional capability by investing in teams that bridge biology, process engineering, regulatory affairs, and market access. This organizational coherence enables faster decision-making under uncertainty, smoother technology transfers, and more defensible positioning in negotiations with partners and payers. Implementing these actions will support both near-term trial continuity and long-term commercialization success.

A robust mixed-methods approach combining expert interviews, regulatory review, and scenario analysis to deliver program-specific and operationally actionable insights

The research methodology underpinning this analysis combines qualitative synthesis of clinical development trends, regulatory guidance review, and cross-industry operational practices to produce actionable insights. Primary inputs included structured interviews with clinical development leaders, manufacturing and supply chain executives, and regulatory affairs specialists, supplemented by peer-reviewed literature, regulatory communications, and product-specific technical disclosures. The analysis emphasized triangulation across sources to validate observed shifts in delivery technologies, process improvements, and regional capacity expansion.

Analysts applied a segmentation framework that integrates therapy modality, vector type, cell biology, indication focus, and trial phase to ensure that recommendations are context-sensitive and operationally relevant. Scenario analysis was used to assess the implications of trade policy changes, supply chain shocks, and manufacturing innovations on trial continuity and program economics. Wherever possible, methodological transparency was maintained by documenting assumptions about supply chain dependencies, regulatory timelines, and technology readiness levels.

Limitations of the methodology are acknowledged: rapidly evolving clinical data and proprietary manufacturing practices can alter program trajectories, and regional regulatory decisions may shift in response to new evidence. To mitigate these constraints, the approach emphasizes regularly updated advisories and the option for customized deep-dive analyses tailored to specific programs and partnership scenarios.

A concise synthesis of strategic imperatives that reconcile scientific innovation with operational resilience to advance clinical programs and patient access

In conclusion, the clinical trials landscape for cell and gene therapies is at an inflection point where scientific opportunity converges with heightened operational complexity. Progress in delivery technologies, vector engineering, and manufacturing automation creates pathways to broader therapeutic impact, yet these gains are accompanied by supply chain fragility, regulatory scrutiny, and the need for scaled manufacturing solutions. Sponsors that proactively integrate modality selection, vector strategy, cell-source considerations, indication-specific design, and phase-appropriate evidence generation will navigate development risks more effectively.

Regional dynamics and recent trade policy developments further underscore the importance of resilient supply chains, diversified manufacturing footprints, and carefully sequenced regulatory engagement. Achieving program success requires harmonizing translational science with process development and commercial foresight, and assembling cross-functional teams capable of executing on complex, interconnected objectives. Ultimately, organizations that prioritize standardization where possible, preserve flexibility where necessary, and maintain close dialogue with regulators and manufacturing partners will be best positioned to translate clinical innovation into sustainable patient impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Expansion of allogeneic CAR-T therapies targeting solid tumors with off-the-shelf solutions
  • 5.2. Integration of gene editing tools like base editing to increase safety in hemophilia trials
  • 5.3. Adoption of next-generation viral vectors to improve transduction efficiency in T-cell therapies
  • 5.4. Development of non-viral delivery platforms for in vivo gene therapies to reduce immunogenicity
  • 5.5. Implementation of decentralized manufacturing models to scale cell therapy production globally

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Cell & Gene Therapy Clinical Trials Market, by Therapy Type

  • 8.1. Cell Therapy
    • 8.1.1. CAR T Cell
    • 8.1.2. Dendritic Cell Therapy
    • 8.1.3. NK Cell Therapy
    • 8.1.4. Stem Cell Therapy
  • 8.2. Gene Therapy
    • 8.2.1. Non-Viral Vector
      • 8.2.1.1. Electroporation
      • 8.2.1.2. Lipid Nanoparticle
      • 8.2.1.3. Naked DNA/RNA
    • 8.2.2. Viral Vector
      • 8.2.2.1. Adeno-Associated Virus
      • 8.2.2.2. Adenoviral
      • 8.2.2.3. Retroviral
  • 8.3. Tissue Engineered Products

9. Cell & Gene Therapy Clinical Trials Market, by Vector Type

  • 9.1. Non-Viral Vector
    • 9.1.1. Electroporation
    • 9.1.2. Lipid Nanoparticle
    • 9.1.3. Naked DNA/RNA
  • 9.2. Viral Vector
    • 9.2.1. Adeno-Associated Virus
    • 9.2.2. Adenoviral
    • 9.2.3. Retroviral

10. Cell & Gene Therapy Clinical Trials Market, by Cell Type

  • 10.1. Dendritic Cell
  • 10.2. NK Cell
  • 10.3. Stem Cell
    • 10.3.1. Hematopoietic Stem Cell
    • 10.3.2. Mesenchymal Stem Cell
  • 10.4. T Cell
    • 10.4.1. CAR T
    • 10.4.2. TCR

11. Cell & Gene Therapy Clinical Trials Market, by Indication

  • 11.1. Neurology
    • 11.1.1. Alzheimer Disease
    • 11.1.2. Parkinson Disease
  • 11.2. Oncology
    • 11.2.1. Hematologic Cancer
      • 11.2.1.1. Leukemia
      • 11.2.1.2. Lymphoma
    • 11.2.2. Solid Tumor
      • 11.2.2.1. Breast Cancer
      • 11.2.2.2. Melanoma
  • 11.3. Rare Disease
    • 11.3.1. Genetic Disorder
      • 11.3.1.1. Cystic Fibrosis
      • 11.3.1.2. Hemophilia
    • 11.3.2. Metabolic Disorder

12. Cell & Gene Therapy Clinical Trials Market, by Trial Phase

  • 12.1. Phase I
  • 12.2. Phase II
  • 12.3. Phase III

13. Cell & Gene Therapy Clinical Trials Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Cell & Gene Therapy Clinical Trials Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Cell & Gene Therapy Clinical Trials Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. Competitive Landscape

  • 16.1. Market Share Analysis, 2024
  • 16.2. FPNV Positioning Matrix, 2024
  • 16.3. Competitive Analysis
    • 16.3.1. Novartis AG
    • 16.3.2. Gilead Sciences, Inc.
    • 16.3.3. Spark Therapeutics, Inc.
    • 16.3.4. bluebird bio, Inc.
    • 16.3.5. Sangamo Therapeutics, Inc.
    • 16.3.6. CRISPR Therapeutics AG
    • 16.3.7. Editas Medicine, Inc.
    • 16.3.8. Fate Therapeutics, Inc.
    • 16.3.9. Orchard Therapeutics Ltd
    • 16.3.10. uniQure N.V.

LIST OF FIGURES

  • FIGURE 1. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2024 VS 2032 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024 VS 2032 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2032 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TRIAL PHASE, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AMERICAS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. NORTH AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. LATIN AMERICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. EUROPE CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. MIDDLE EAST CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. AFRICA CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. ASIA-PACIFIC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. ASEAN CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. GCC CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 24. EUROPEAN UNION CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 25. BRICS CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 26. G7 CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 27. NATO CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 28. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 29. CELL & GENE THERAPY CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 30. CELL & GENE THERAPY CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY THERAPY TYPE, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY GENE THERAPY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TISSUE ENGINEERED PRODUCTS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VECTOR TYPE, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NON-VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ELECTROPORATION, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LIPID NANOPARTICLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NAKED DNA/RNA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY VIRAL VECTOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENO-ASSOCIATED VIRUS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ADENOVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY RETROVIRAL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CELL TYPE, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY DENDRITIC CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NK CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, 2025-2032 (USD MILLION)
  • TABLE 175. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 176. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 177. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 178. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 179. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 180. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 181. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 182. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 183. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 184. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 185. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 186. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOPOIETIC STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 187. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 188. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 189. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 190. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 191. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 192. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MESENCHYMAL STEM CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 193. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2018-2024 (USD MILLION)
  • TABLE 194. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, 2025-2032 (USD MILLION)
  • TABLE 195. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 196. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 197. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 198. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 199. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 200. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY T CELL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 201. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 202. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 203. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 204. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 205. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 206. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY CAR T, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 207. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 208. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 209. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 210. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 211. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 212. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY TCR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 213. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2018-2024 (USD MILLION)
  • TABLE 214. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY INDICATION, 2025-2032 (USD MILLION)
  • TABLE 215. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2018-2024 (USD MILLION)
  • TABLE 216. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, 2025-2032 (USD MILLION)
  • TABLE 217. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 218. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 219. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 220. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 221. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 222. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY NEUROLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 223. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 224. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 225. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 226. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 227. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 228. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ALZHEIMER DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 229. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 230. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 231. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 232. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 233. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 234. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY PARKINSON DISEASE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 235. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2018-2024 (USD MILLION)
  • TABLE 236. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, 2025-2032 (USD MILLION)
  • TABLE 237. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 238. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 239. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 240. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 241. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 242. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 243. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2018-2024 (USD MILLION)
  • TABLE 244. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, 2025-2032 (USD MILLION)
  • TABLE 245. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 246. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 247. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 248. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 249. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 250. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY HEMATOLOGIC CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 251. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 252. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 253. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 254. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 255. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LEUKEMIA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 258. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 259. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 260. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 261. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 262. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY LYMPHOMA, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 263. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2018-2024 (USD MILLION)
  • TABLE 264. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, 2025-2032 (USD MILLION)
  • TABLE 265. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 266. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 267. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 268. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 269. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 270. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY SOLID TUMOR, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 271. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 272. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 273. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 274. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 275. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY BREAST CANCER, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE, BY MELANOMA, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 278. GLOBAL CELL & GENE THERAPY CLINICAL TRIALS MARKET SIZE